Drug recall · January 8, 2020
RANITIDINE TABLETS recall
Why: CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
RANITIDINE TABLETS, USP 150mg, 10,000-count bag, Country of Origin: INDIA NDC 62207-773-32
- Lots / codes
7730001A, 7730002A, 7730003A, 7730004A, 7730005A, 7730006A, 7730007A, 7730008A, 7730009A, 7730010A, 7730011A and 7730012A
- Quantity
- 23,090,000 tablets
- Company
- Granules India Limited, Qutbullapur Mandal, Ranga Redd, N/A
- Distribution
- OR, NY, NJ
- Initiated
- December 13, 2019 · Voluntary: Firm initiated
- Classified
- December 29, 2019
- Reported
- January 8, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ranitidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.